AI Scribe Maker Suki Raises $90 Million Series E as Ambient Clinical AI Nears $80 Million in Revenue

Suki, the Redwood City company behind one of the most widely used ambient AI scribes in US healthcare, has raised a $90 million Series E. The round was led by Healthier Capital, with Crosslink Capital, Zoom Ventures, Philips Ventures and Hercules Capital co-leading, and participation from Venrock, Flare Capital Partners and Hedosophia. No valuation was disclosed; Suki's previous round, a $70 million Series D in October 2024, valued the company at about $500 million according to Reuters.

Suki's product listens to the conversation between a clinician and a patient and drafts the clinical note — the physician reviews and signs, and the software does not close the encounter or file the claim on its own. That "the model drafts, a human signs" boundary has become the clearest product-market fit in health AI, because the problem it attacks is acute: doctors spend an outsized share of their day on paperwork. The company says its assistant is now used by more than 450 healthcare organizations across more than 100 specialties.

The commercial traction is why the round happened at all. Suki doubled its recurring revenue in 2025 and is on track to repeat that in 2026, and a source told Axios the company projects $60 million to $80 million in revenue this year — a company-sourced projection, not an audited figure. Founded in 2015 by Punit Soni, a former product leader at Google and Flipkart, Suki has now raised seven rounds over roughly a decade, totaling more than $255 million — a slow-burn pace that looks deliberate next to the two-year funding sprints typical elsewhere in AI.

The new capital is earmarked for the step beyond transcription: agentic execution of post-encounter work, such as staging orders, routing referrals and dispatching scheduling — tasks where a wrong output carries clinical and legal consequences. Suki is also scaling its platform business: its speech recognition and ambient AI stack is already licensed as an SDK to more than 30 third-party health technology companies, including Zoom, which builds it into its own clinical workflow products.

Suki's trajectory is a useful read on where practical agent deployments are landing first. The most commercial form of the "AI agent" is not an autonomous system loose on the internet; it is a system that does the labor while a licensed professional keeps the entry point — in healthcare because regulation demands it, and increasingly everywhere else because it is simply good engineering.